The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
... Moreover, a side door for patients is now open in the UK to access these powerful, effective drugs, besmirched by suspicion and fear probably, through the NHS's Refractory Epilepsy Specialist Clinical Advisory Service. This is finally happening. This company has shown their hand and determination to succeed in very difficult circumstances. Massive Congratulations. Its snow balling time!
Brilliant news from MGC today re the first UK patient to receive CannEpil for epilepsy treatment. As many have posted on here for quite some time we know that there is a massive unmet need for epilepsy treatment in the UK and worldwide. The big news contained in the RNS today is confirmation that CannEpil is being prescribed via Named Patient Request for the first time. In summary, MGC is making significant progress in the epilepsy space. This is a very big market with latest research highlighting that nine people in every 1,000 people have epilepsy each year in the UK. This means that an estimated 633,000 people are living with epilepsy in the UK. Globally the figure is huge with approx 50 million people having epilepsy, making it one of the most common neurological diseases. This is a big day for MGC investors.
Good luck, Brighty
Nothing but sells all day but who's buying them 🤔????
That aged well, another new low, congrats mgc!
Noba .......it is new low
New low :)
When management sell shares at sxxxe prices you know the ship is holed below the waterline....
This share resembles the title... Sadly this is dwindling to zero as no serious path is being laid...
Just need sales, then the facility will no longer be a tourist attraction but a fully working production facility :) onwards and upwards. .
More excellent news today from MGC regarding its Malta production facility gaining EU-GMP sign off. This is a major milestone for the company.
Key messaging today:
* "It further enhances MGC's production capabilities for its future expansion, guaranteeing its ability to supply large volumes of its products to its customers and distribution partners of high pharma standards, and quality into the future." - CEO
* The production facility, built with the support of an 80% total cost EU cash grant from Malta Enterprise integrates the full MGC value chain of research, investigational medicinal products, and commercial production.
* Good Manufacturing Practice accreditation is the highest standard that a medicinal product manufacturer needs to meet in production processes. This certification ensures that the products are of a high quality and are appropriate for their intended use. Importantly, the GMP certification is recognised by the USA Food and Drug Administration (FDA), enabling products produced at the facility to be imported for sale in the US.
* MGC's in house production capacity in Malta is now over 20,000 units a day of finish dose forms, which can support all future needs of CannEpil® and CimetrA™ once marketing authorisation is obtained in USA and Europe.
Summary: Another great piece of the MGC jigsaw completed today.
Good luck, Brighty
Or spending his money
Noba
Please don’t buy this
2x massive buys today so far
Very honest.
Omapny is very reliant on the loans. The cannepil will take this to new levels it works wonders i heard.
It's only for the ASX:
The securities of MGC Pharmaceuticals Ltd (‘MXC’) will be placed in trading halt at the request of MXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 13 April 2023 or when the announcement is released to the market.
Jeeez, did mgc hear me? Fantastic news!! That will be in media for sure! But came with the beggin bowl and of course no one likes it. Onwards and upwards now!!!
I've just bought some more too (though God knows why!!!???!!!!). Still, an average of .77 is better than 2.96.
Don't play with what you can't afford to lose! ??
Trading halt ? Nonsense, last trade on my screen at 10.39, 590,000 @ 0.43.
How is it no one has mentioned this and not showing in RNS
Welcome news:
European pharmaceutical company offers its investigational medicinal product to a wide range of specialist medical practitioners in the United Kingdom
Epidiolex's Success Highlights Potential for MGC Pharma's CannEpil®
The recent success of Epidiolex, a CBD-based epilepsy treatment that generated $296 million in sales in 2019, highlights the potential for MGC Pharma's CannEpil® in the UK market. This underlines the potential of CannEpil®, an investigational medicinal product for patients suffering from refractory epilepsy, to make a significant impact in the UK market.
https://finance.yahoo.com/news/mgc-pharmas-cannepil-now-accessible-060000251.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAADm4Mwm_WoC548JKadPkCk0ChtSbnisGYmYJ3-YZVXNZ9R3WOrukywIzNztLhI_9t3kbtV9DN_gPiRWlHq3gWC_ahJZsIf2lN4_IBXwAAVtUb5J4PPu0flOxGJ5ezgPKGylgpVTxv167rEkZvL-gFaXLUV4ij2ParyBmla4ZUQ_X
Here is the big epilepsy news many of us have been expecting, waiting and hoping for:
* "CannEpil® now available by Named Patient Request in UK"
* "The availability of CannEpil® by Named Patient Request marks a momentous breakthrough for MGC Pharma. The product will now be available to a wide cohort of specialist medical practitioners in the UK, which is testament to the progress we are making." - MGC
* "CannEpil's® availability in the UK for unmet medical need by doctors on the GMC specialist register, is another material milestone for the company within the healthcare and Life-Science sector as an innovative plant-inspired pharmaceutical company". - MGC
Plus £1.2 million raised in a conditional Placing, including CannEpil Phase 2b clinical trial funding secured up to c.£0.63 million plus UK Broker Option Share offer to raise up to £0.75 million.
Summary and key message: Epilepsy impacts approx 50 million people worldwide, so this is big news....
Good luck, Brighty
I would like to think so. More calls in the news for governnent to fund research in medical canabis for epilepsy, cmon mgc where is the uk with the cannapil trials? Time for a push me thinks!